TY  - JOUR
AU  - Recher, Christian
AU  - Röllig, Christoph
AU  - Berard, Emilie
AU  - Bertoli, Sarah
AU  - Dumas, Pierre-Yves
AU  - Tavitian, Suzanne
AU  - Kramer, Michael
AU  - Serve, Hubert
AU  - Bornhäuser, Martin
AU  - Platzbecker, Uwe
AU  - Müller-Tidow, Carsten
AU  - Baldus, Claudia D
AU  - Martinez-Cuadron, David
AU  - Serrano, Josefina
AU  - Martinez-Sanchez, Pilar
AU  - Arboli, Eduardo Rodriguez
AU  - Gil, Cristina
AU  - Bergua, Juan
AU  - Bernal, Teresa
AU  - de la Fuente Burguera, Adolfo
AU  - Delabesse, Eric
AU  - Bidet, Audrey
AU  - Pigneux, Arnaud
AU  - Montesinos, Pau
PY  - 2021
DO  - 10.1038/s41375-021-01425-9
UR  - http://hdl.handle.net/10668/22599
T2  - Leukemia
AB  - The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric...
LA  - en
PB  - Nature Publishing Group
KW  - Leukemia, myeloid, acute
KW  - Registries
KW  - Treatment outcome
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic combined chemotherapy protocols
KW  - Azacitidine
KW  - Humans
KW  - Registries
TI  - Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
TY  - research article
VL  - 36
ER  -